Evidence map›Paper›PMID 42604028›Full record

ArticleJournal of pharmaceutical analysis2026

Aptamer-based nanoparticle drug delivery system designed for targeting GPC3-positive liver cancer.

Hongxin Zhou, Shuangshuang Dong, Zhan Si, Hao Niu, Jianwen Mao, Yiran Chen, Yuhuan Li, Weizhong Wu

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of pharmaceutical analysis, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Hongxin ZhouLiver Cancer Institute, Zhongshan Hospital, Key Laboratory of Carcinogenesis and Cancer Invasion, Ministry of Education, Fudan University, Shanghai, 200032, China.
Shuangshuang DongLiver Cancer Institute, Zhongshan Hospital, Key Laboratory of Carcinogenesis and Cancer Invasion, Ministry of Education, Fudan University, Shanghai, 200032, China.
Zhan SiDepartment of Nuclear Medicine, Zhongshan Hospital, Fudan University, Shanghai, 200032, China.
Hao NiuLiver Cancer Institute, Zhongshan Hospital, Key Laboratory of Carcinogenesis and Cancer Invasion, Ministry of Education, Fudan University, Shanghai, 200032, China.
Jianwen MaoLiver Cancer Institute, Zhongshan Hospital, Key Laboratory of Carcinogenesis and Cancer Invasion, Ministry of Education, Fudan University, Shanghai, 200032, China.
Yiran ChenLiver Cancer Institute, Zhongshan Hospital, Key Laboratory of Carcinogenesis and Cancer Invasion, Ministry of Education, Fudan University, Shanghai, 200032, China.
Yuhuan LiLiver Cancer Institute, Zhongshan Hospital, Key Laboratory of Carcinogenesis and Cancer Invasion, Ministry of Education, Fudan University, Shanghai, 200032, China.
Weizhong WuLiver Cancer Institute, Zhongshan Hospital, Key Laboratory of Carcinogenesis and Cancer Invasion, Ministry of Education, Fudan University, Shanghai, 200032, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Nucleic acid aptamers, short single-stranded DNA (ssDNA) or RNA molecules generated via systematic evolution of ligands by exponential enrichment (SELEX), have emerged as promising alternatives to traditional antibodies owing to their exceptional specificity and affinity. These unique properties render them invaluable tools in both scientific research and clinical theranostics. In recent years, aptamer-functionalized nanomaterials have demonstrated substantial potential as tumor-targeted drug delivery systems, offering notable advantages such as reduced systemic toxicity and enhanced therapeutic efficacy. In this study, we developed a novel targeted drug delivery system specifically designed for glypican-3 (GPC3)-positive hepatocellular carcinoma (HCC) by conjugating the GPC3-targeted aptamer AP613-1 to liposomes encapsulating doxorubicin (DOX). To enhance the biostability and binding affinity of the aptamer, we constructed an aptamer-embedded triangular nanostructure (mTriangle-AP613-1) using a DNA origami technique. Characterization results revealed that the mTriangle-AP613-1 nanostructure exhibited a significantly improved dissociation constant (

Indexed as

DNA origamiDoxorubicinDrug delivery systemGlypican-3Nucleic acid aptamers

Identifiers

PMID42604028
PMCPMC13476555

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.